OS Therapies Sets May 18 Q1 Results; Highlights Positive Phase 2b OST-HER2 Data
OS Therapies will release Q1 2026 financial results and provide a business update on May 18, 2026 covering revenue trends, expenses and cash position. The clinical-stage biotech highlighted positive Phase 2b data for its lead OST-HER2 immunotherapy, anticipates a BLA submission and European conditional authorizations this year and expects Phase 1b OST-504 prostate cancer data in H1 2026.
1. Earnings Release Schedule
OS Therapies will announce Q1 2026 financial results and deliver a business update on May 18, 2026, covering revenue trends, expenses and cash position. Management is expected to discuss operating milestones and funding runway into 2027.
2. Positive Phase 2b Trial Results
In its Phase 2b study of OST-HER2 in recurrent, fully resected lung metastatic osteosarcoma, the company reported clinically significant improvements in the 12-month event free survival primary endpoint and in the overall survival secondary endpoint.
3. Regulatory Milestones and Pipeline Outlook
The company anticipates submitting a BLA for OST-HER2 in osteosarcoma and securing conditional marketing authorizations from the U.K. and EMA in 2026, plus a Phase 1b OST-504 prostate cancer data readout in H1 2026. Its next-generation tADC platform also advances with proprietary Si-Linker and CAP payload technologies.